Kate Keenan1, Alison Hipwell2, Rose McAloon2, Amy Hoffmann2, Arpita Mohanty2, Kelsey Magee2. 1. University of Chicago, Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 South Maryland Avenue, Chicago IL, 60637, USA. Electronic address: kekeenan@uchicago.edu. 2. University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Abstract
IMPORTANCE: African American women living in urban, low-income environments are at high risk for poor nutrition during pregnancy and birth complications. OBJECTIVE: To test the effectiveness of prenatal docosahexaenoic acid (DHA) supplementation on birth outcomes and infant development in a sample of African American women with Medicaid insurance and living in the city of Pittsburgh. DESIGN: The Nutrition and Pregnancy Study (NAPS) is a double-blind, randomized controlled trial of prenatal DHA supplementation conducted between 2012 and 2014. SETTING:Participants were recruited from obstetric clinics at the University of Pittsburgh Medical Center. PARTICIPANTS: Sixty-four pregnant, African American women were enrolled at 16-21 weeks of gestation and randomized to either450mg/day of DHA (22:6n-3)(n=43) or a soybean placebo (n=21). Four women (6.3%) withdrew from the study: two participants from each study arm; complete data were obtained for 49 infants (76.5%) at the 3-month assessment. INTERVENTIONS: Supplementation with DHA or placebo continued from the beginning of enrollment through delivery. MAIN OUTCOME AND MEASURES: Data on birth outcomes were collected from medical records. At approximately 3 months post-partum, mothers brought their infants to the laboratory where the Bayley Scales of Infant Development (BSID-III) were administered and cortisol response to the Face-to-Face Still-Face (FFSF) paradigm was assessed. RESULTS: Infants of mothers who received DHA supplementation had higher birth weight (3.174g versus 2.890g) than infants of mothers receiving placebo (F [2.40]=6.09, p=0.018, eta=0.36), and were more likely to have a 1-min Apgar score greater than 8 (OR=5.99 [95% CI=1.25-28.75], p=0.025). Infants of mothers who received DHA compared with infants of mothers receiving placebo had lower levels of cortisol in response to the FFSF paradigm (F [1.32]=5.36, p=0.018, eta=0.36). None of the scores on the BSID-III differed as a function of active supplement versus placebo. CONCLUSIONS:Infants of women living in urban, low-income environments who receivedDHA supplementation had more optimal birth outcomes and more modulated cortisol response to a stressor. DHA supplementation may be effective in attenuating the negative effects of prenatal stress on offspring development.
RCT Entities:
IMPORTANCE: African American women living in urban, low-income environments are at high risk for poor nutrition during pregnancy and birth complications. OBJECTIVE: To test the effectiveness of prenatal docosahexaenoic acid (DHA) supplementation on birth outcomes and infant development in a sample of African American women with Medicaid insurance and living in the city of Pittsburgh. DESIGN: The Nutrition and Pregnancy Study (NAPS) is a double-blind, randomized controlled trial of prenatal DHA supplementation conducted between 2012 and 2014. SETTING:Participants were recruited from obstetric clinics at the University of Pittsburgh Medical Center. PARTICIPANTS: Sixty-four pregnant, African American women were enrolled at 16-21 weeks of gestation and randomized to either 450mg/day of DHA (22:6n-3)(n=43) or a soybean placebo (n=21). Four women (6.3%) withdrew from the study: two participants from each study arm; complete data were obtained for 49 infants (76.5%) at the 3-month assessment. INTERVENTIONS: Supplementation with DHA or placebo continued from the beginning of enrollment through delivery. MAIN OUTCOME AND MEASURES: Data on birth outcomes were collected from medical records. At approximately 3 months post-partum, mothers brought their infants to the laboratory where the Bayley Scales of Infant Development (BSID-III) were administered and cortisol response to the Face-to-Face Still-Face (FFSF) paradigm was assessed. RESULTS:Infants of mothers who received DHA supplementation had higher birth weight (3.174g versus 2.890g) than infants of mothers receiving placebo (F [2.40]=6.09, p=0.018, eta=0.36), and were more likely to have a 1-min Apgar score greater than 8 (OR=5.99 [95% CI=1.25-28.75], p=0.025). Infants of mothers who received DHA compared with infants of mothers receiving placebo had lower levels of cortisol in response to the FFSF paradigm (F [1.32]=5.36, p=0.018, eta=0.36). None of the scores on the BSID-III differed as a function of active supplement versus placebo. CONCLUSIONS:Infants of women living in urban, low-income environments who received DHA supplementation had more optimal birth outcomes and more modulated cortisol response to a stressor. DHA supplementation may be effective in attenuating the negative effects of prenatal stress on offspring development.
Authors: Michelle Bosquet Enlow; Lucy King; Hannah Mc Schreier; Jamie M Howard; David Rosenfield; Thomas Ritz; Rosalind J Wright Journal: Early Hum Dev Date: 2014-05-01 Impact factor: 2.079
Authors: Maria Makrides; Robert A Gibson; Andrew J McPhee; Lisa Yelland; Julie Quinlivan; Philip Ryan Journal: JAMA Date: 2010-10-20 Impact factor: 56.272
Authors: Julie E H Nevins; Sharon M Donovan; Linda Snetselaar; Kathryn G Dewey; Rachel Novotny; Jamie Stang; Elsie M Taveras; Ronald E Kleinman; Regan L Bailey; Ramkripa Raghavan; Sara R Scinto-Madonich; Sudha Venkatramanan; Gisela Butera; Nancy Terry; Jean Altman; Meghan Adler; Julie E Obbagy; Eve E Stoody; Janet de Jesus Journal: J Nutr Date: 2021-11-02 Impact factor: 4.687
Authors: Brietta M Oaks; Seth Adu-Afarwuah; Sika Kumordzie; Mark L Laudenslager; Dana L Smith; Jue Lin; Rebecca R Young; Charles D Arnold; Helena Bentil; Harriet Okronipa; Maku Ocansey; Kathryn G Dewey Journal: Stress Date: 2020-02-24 Impact factor: 3.493